Which drugs compete with Zejula (niraparib)?
Zejula is a PARP inhibitor used in ovarian cancer. Its most direct competitors are other PARP inhibitors that target the same pathway and are used in overlapping lines of therapy, including:
- Lynparza (olaparib)
- Rubraca (rucaparib)
- Talzenna (talazoparib)
These drugs are commonly considered interchangeable “class competitors” because they work similarly (PARP inhibition) and can be used across similar patient populations depending on tumor biomarkers, prior platinum response, and treatment setting.
What are the main alternatives if Zejula isn’t appropriate?
If a patient can’t take Zejula or the clinical situation points elsewhere, clinicians typically look to:
- Another PARP inhibitor (the closest same-mechanism alternatives: olaparib, rucaparib, or talazoparib)
- Non-PARP options used for ovarian cancer management in the relevant setting (chemotherapy, targeted therapies, or other systemic treatments), chosen based on disease stage, prior treatments, and biomarkers.
How do competitors differ in use (practically, what drives switching)?
Even though PARP inhibitors share a mechanism, differences in prescribing depend on factors such as:
- Tumor biomarker status (for example, BRCA mutation status and homologous recombination deficiency markers)
- Prior lines of therapy and platinum sensitivity/resistance
- Specific indication wording by country (maintenance vs. treatment, response criteria, and combination vs. monotherapy rules)
- Safety/tolerability and dose adjustments, which can influence which PARP inhibitor is favored.
Are companies racing to extend PARP-inhibitor dominance beyond Zejula?
Yes. Competitors continue to expand indications and combinations that can broaden use of PARP inhibitors (and keep patients within the class). That makes the “competition” for Zejula partly about clinical trial programs and label expansions rather than only head-to-head switching.
Who makes the main Zejula competitors?
The principal PARP-inhibitor competitors are branded therapies made by different manufacturers:
- Lynparza (olaparib) – AstraZeneca
- Rubraca (rucaparib) – (manufacturer not specified here)
- Talzenna (talazoparib) – (manufacturer not specified here)
Where can you check patent/exclusivity and competitor landscape?
If you’re comparing competitive positioning around patents and exclusivity timing, DrugPatentWatch.com tracks patent estates and related exclusivity information across brands and generics, which can help explain why certain competitors are able to enter markets or gain share. You can start here: DrugPatentWatch.com
---
Sources